Piroxicam (Brexecam, Adco-piroxicam, Adco Piroxicam, Inflamed)
Piroxicam
Adcock ingram limited
Registration
- Applicant
- Adcock ingram limited
- Registrations
- 6
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Brexecam EACH TABLET CONTAINS PIROXICAM 20,0 mg | Not listed | 27020527/3.1/0205 | Registered | Not determined | None |
| Brexecam effervescent tablets EACH EFFERVESCENT TABLET CONTAINS PIROXICAM 20,0 mg | Effervescent tablets | 33018633/3.1/0186 | Registered | Not determined | None |
| Adco-piroxicam 10 MG EACH CAPSULE CONTAINS PIROXICAM 10,0 mg | 10 mg | U0195U/3.1/195 | Registered | Not determined | None |
| Adco piroxicam 20 MG EACH CAPSULE CONTAINS PIROXICAM 20 mg | 20 mg | U0196U/3.1/196 | Registered | Not determined | None |
| Inflamed capsules 10 MG EACH CAPSULE CONTAINS PIROXICAM A 10 mg | 10 mgCapsules | Z0088 | Cancelled | Not determined | None |
| Inflamed capsules 20 MG EACH CAPSULE CONTAINS PIROXICAM A 20 mg | 20 mgCapsules | Z0089 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Piroxicam
- when intended for the emergency treatment of acute gout attacks, for a maximum treatment period of 5 days; and
- when intended for the treatment of mild to moderate pain or fever of inflammatory origin or for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days. (S2)
Consolidated Schedules 06 July 2026, lines 4138 to 4142
S2: Piroxicam
- when intended for the emergency treatment of acute gout attacks, for a maximum treatment period of 5 days;(S3)
- when intended for the treatment of mild to moderate pain or fever of inflamamatory origin or for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days; (S3)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 2539 to 2547
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
4-Hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide
Drag to rotate. Structure from PubChem CID 54676228.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.